Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department has taken to help ensure that there is long-term monitoring of the immune response of people given a covid-19 booster vaccine.

The UK Health Security Agency (UKHSA) continuously monitors vaccine effectiveness over time. These analyses will continue as the booster programme deployment progresses, including the duration of protection of booster doses against a range of disease outcomes and will be published in due course.

The UKHSA observed limited waning in vaccine effectiveness against hospitalisation and death more than 20 weeks post-vaccination with Vaxzevria (previously AstraZeneca) or Comirnaty (previously Pfizer) with the Delta variant. Early data suggest vaccine effectiveness is lower against the Omicron variant. However, high levels of protection against symptomatic disease were seen shortly after a booster dose. Further evidence is needed to understand the effect of the Omicron variant on duration of protection and vaccine effectiveness against severe disease.

The primary objective of the booster programme is to maintain protection against severe COVID-19 disease, specifically hospitalisation and deaths, over winter 2021/22. This is exceptional advice aimed at maintaining protection in those most vulnerable and to protect the National Health Service.